MGMT and central nervous system cancer: Considering the available data and the need for improved, non-invasive characterization of gliomas, the aim of this study was to evaluate whether whole tumor HA of ADC profiles has the ability to (i) differentiate LGG from HGG, (ii) predict the proliferative activity of the glioma represented by Ki-67 immunolabelling and (iii) predict the prognostic relevant MGMT (methylguanine-DNA methyl-transferase) MGMT methylation profile, as well as the IDH (isocitrate dehydrogenase) mutation profile.